Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/41937| Title: | Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study | Authors: | Decoster, L. Aftimos, P. G. Rottey, S. Prenen, H. Collignon, J. J. MEBIS, Jeroen Canon, J-L. Fastenaekels, V. Cappoen, N. Joris, S. R. De Greve, J. |
Issue Date: | 2023 | Publisher: | ELSEVIER | Source: | ANNALS OF ONCOLOGY, 34 , p. S262 | Abstract: | Background: The Belgian Precision initiative aims to implement tumor-agnostic NGS in advanced cancer patients (pts) and enhance access to genotype-matching drugs. The current study aimed to investigate the efficacy of afatinib in advanced pre-treated solid cancers with an EGFR (excluding non-small cell lung cancer (NSCLC)), HER2 or HER3 mutation. | Keywords: | Interests, Personal, Full or part-time Employment: CDR-Life;Other, Personal, Project Lead: CDR-Life L Borras: Financial Interests, Personal, Full or part-time Employment: CDR-Life;Financial Interests, Personal, Leadership Role: CDR-Life;Financial Interests, Personal, Stocks/Shares: CDR-Life S Biswas: Financial Interests, Personal, Full or part-time Employment: CDR-Life R Leidner: Financial Interests, Personal, Advisory Role: Bristol Myers Squibb;Financial Interests, Personal, Project Lead: Bristol Myers Squibb, Incycte E Calvo: Financial Interests, Personal, Advisory Board: Adcendo, Amunix, Anaveon, AstraZeneca, BMS, Janssen, MonTa, MSD, Nanobiotix, Nouscom, Novartis, Servier, Tar- gImmune, T-knife, Chugai, Elevation Oncology, Ellipses Pharmacy, SyneosHealth, Genmab, Diac- curate;Financial Interests, Personal, Invited Speaker: OncoDNA, PharmaMar, Roche/Genentech;Financial Interests, Personal, Full or part-time Employment, Director, Clinical Research: HM Hospi- tales Group;Financial Interests, Personal, Full or part-time Employment, Medical Oncologist Clinical Investigator Director, Clinical Research: START Madrid -CIOCC (Centro Integral Oncológico Clara Campal);Financial Interests, Personal, Member of Board of Directors, External Independent member of Board of Directors: PharmaMar;Financial Interests, Personal, Ownership Interest: START, Oncoart Associated;Financial Interests, Personal, Steering Committee Member, Member of Data Monitoring Committee: BeiGene, Sanofi, Merus;Financial Interests, Personal, Steering Committee Member: Novartis;Non-Financial Interests, Other, Non-for-profit Foundation President and co-founder: INTHEOS (Investigational Therapeutics in Oncological Sciences) non-for-profit Foundation;Non- Financial Interests, Advisory Role: PsiOxus;Non-Financial Interests, Other, Chair of the Independent | Document URI: | http://hdl.handle.net/1942/41937 | ISSN: | 0923-7534 | e-ISSN: | 1569-8041 | DOI: | 10.1016/j.annonc.2023.09.2924 | ISI #: | 001087480200196 | Category: | M | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors_ A phase II Belgian precision study.pdf | Published version | 71.86 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.